1
|
Marforio TD, Carboni A, Calvaresi M. In Vivo Application of Carboranes for Boron Neutron Capture Therapy (BNCT): Structure, Formulation and Analytical Methods for Detection. Cancers (Basel) 2023; 15:4944. [PMID: 37894311 PMCID: PMC10605826 DOI: 10.3390/cancers15204944] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2023] [Revised: 09/22/2023] [Accepted: 10/09/2023] [Indexed: 10/29/2023] Open
Abstract
Carboranes have emerged as one of the most promising boron agents in boron neutron capture therapy (BNCT). In this context, in vivo studies are particularly relevant, since they provide qualitative and quantitative information about the biodistribution of these molecules, which is of the utmost importance to determine the efficacy of BNCT, defining their localization and (bio)accumulation, as well as their pharmacokinetics and pharmacodynamics. First, we gathered a detailed list of the carboranes used for in vivo studies, considering the synthesis of carborane derivatives or the use of delivery system such as liposomes, micelles and nanoparticles. Then, the formulation employed and the cancer model used in each of these studies were identified. Finally, we examined the analytical aspects concerning carborane detection, identifying the main methodologies applied in the literature for ex vivo and in vivo analysis. The present work aims to identify the current strengths and weakness of the use of carboranes in BNCT, establishing the bottlenecks and the best strategies for future applications.
Collapse
Affiliation(s)
| | - Andrea Carboni
- Dipartimento di Chimica “Giacomo Ciamician”, Alma Mater Studiorum—Università di Bologna, Via Francesco Selmi 2, 40126 Bologna, Italy;
| | - Matteo Calvaresi
- Dipartimento di Chimica “Giacomo Ciamician”, Alma Mater Studiorum—Università di Bologna, Via Francesco Selmi 2, 40126 Bologna, Italy;
| |
Collapse
|
2
|
Matović J, Bahrami K, Stockmann P, Sokka IK, Khng YC, Sarparanta M, Hey-Hawkins E, Rautio J, Ekholm FS. Sweet Battle of the Epimers─Continued Exploration of Monosaccharide-Derived Delivery Agents for Boron Neutron Capture Therapy. Mol Pharm 2023. [PMID: 37134022 DOI: 10.1021/acs.molpharmaceut.3c00119] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/04/2023]
Abstract
Boron neutron capture therapy (BNCT) is a cancer therapy in which boron delivery agents play a crucial role. In theory, delivery agents with high tumor targeting capabilities can lead to selective eradication of tumor cells without causing harmful side effects. We have been working on a GLUT1-targeting strategy to BNCT for a number of years and found multiple promising hit compounds which outperform the clinically employed boron delivery agents in vitro. Herein, we continue our work in the field by further diversification of the carbohydrate scaffold in order to map the optimal stereochemistry of the carbohydrate core. In the sweet battle of the epimers, carborane-bearing d-galactose, d-mannose, and d-allose are synthesized and subjected to in vitro profiling studies─with earlier work on d-glucose serving as the reference. We find that all of the monosaccharide delivery agents display a significantly improved boron delivery capacity over the delivery agents approved for clinical use in vitro, thus providing a sound foundation for advancing toward in vivo preclinical assessment studies.
Collapse
Affiliation(s)
- Jelena Matović
- Department of Chemistry, University of Helsinki, Finland, P.O. Box 55, Helsinki FI-00014, Finland
| | - Katayun Bahrami
- School of Pharmacy, University of Eastern Finland, P.O. Box 1627, Kuopio FI-70211, Finland
| | - Philipp Stockmann
- Faculty of Chemistry and Mineralogy, Institute of Inorganic Chemistry, Leipzig University, Leipzig D-04103, Germany
| | - Iris K Sokka
- Department of Chemistry, University of Helsinki, Finland, P.O. Box 55, Helsinki FI-00014, Finland
| | - You Cheng Khng
- Department of Chemistry, University of Helsinki, Finland, P.O. Box 55, Helsinki FI-00014, Finland
| | - Mirkka Sarparanta
- Department of Chemistry, University of Helsinki, Finland, P.O. Box 55, Helsinki FI-00014, Finland
| | - Evamarie Hey-Hawkins
- Faculty of Chemistry and Mineralogy, Institute of Inorganic Chemistry, Leipzig University, Leipzig D-04103, Germany
| | - Jarkko Rautio
- School of Pharmacy, University of Eastern Finland, P.O. Box 1627, Kuopio FI-70211, Finland
| | - Filip S Ekholm
- Department of Chemistry, University of Helsinki, Finland, P.O. Box 55, Helsinki FI-00014, Finland
| |
Collapse
|
3
|
Matović J, Järvinen J, Sokka IK, Stockmann P, Kellert M, Imlimthan S, Sarparanta M, Johansson MP, Hey-Hawkins E, Rautio J, Ekholm FS. Synthesis and In Vitro Evaluation of a Set of 6-Deoxy-6-thio-carboranyl d-Glucoconjugates Shed Light on the Substrate Specificity of the GLUT1 Transporter. ACS OMEGA 2022; 7:30376-30388. [PMID: 36061667 PMCID: PMC9434784 DOI: 10.1021/acsomega.2c03646] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/11/2022] [Accepted: 08/04/2022] [Indexed: 05/20/2023]
Abstract
Glucose- and sodium-dependent glucose transporters (GLUTs and SGLTs) play vital roles in human biology. Of the 14 GLUTs and 12 SGLTs, the GLUT1 transporter has gained the most widespread recognition because GLUT1 is overexpressed in several cancers and is a clinically valid therapeutic target. We have been pursuing a GLUT1-targeting approach in boron neutron capture therapy (BNCT). Here, we report on surprising findings encountered with a set of 6-deoxy-6-thio-carboranyl d-glucoconjugates. In more detail, we show that even subtle structural changes in the carborane cluster, and the linker, may significantly reduce the delivery capacity of GLUT1-based boron carriers. In addition to providing new insights on the substrate specificity of this important transporter, we reach a fresh perspective on the boundaries within which a GLUT1-targeting approach in BNCT can be further refined.
Collapse
Affiliation(s)
- Jelena Matović
- Department
of Chemistry, University of Helsinki, P.O. Box 55, FI-00014 Helsinki, Finland
| | - Juulia Järvinen
- School
of Pharmacy, University of Eastern Finland, P.O. Box 1627, FI-70211 Kuopio, Finland
| | - Iris K. Sokka
- Department
of Chemistry, University of Helsinki, P.O. Box 55, FI-00014 Helsinki, Finland
| | - Philipp Stockmann
- Institute
of Inorganic Chemistry, Leipzig University, D-04103 Leipzig, Germany
| | - Martin Kellert
- Institute
of Inorganic Chemistry, Leipzig University, D-04103 Leipzig, Germany
| | - Surachet Imlimthan
- Department
of Chemistry, University of Helsinki, P.O. Box 55, FI-00014 Helsinki, Finland
| | - Mirkka Sarparanta
- Department
of Chemistry, University of Helsinki, P.O. Box 55, FI-00014 Helsinki, Finland
| | - Mikael P. Johansson
- Department
of Chemistry, University of Helsinki, P.O. Box 55, FI-00014 Helsinki, Finland
- Helsinki
Institute of Sustainability Science, HELSUS, FI-00014 Helsinki, Finland
- CSC
− IT Center for Science Ltd., P.O. Box 405, FI-02101 Espoo, Finland
| | | | - Jarkko Rautio
- School
of Pharmacy, University of Eastern Finland, P.O. Box 1627, FI-70211 Kuopio, Finland
| | - Filip S. Ekholm
- Department
of Chemistry, University of Helsinki, P.O. Box 55, FI-00014 Helsinki, Finland
| |
Collapse
|
4
|
Sweet Boron: Boron-Containing Sugar Derivatives as Potential Agents for Boron Neutron Capture Therapy. Symmetry (Basel) 2022. [DOI: 10.3390/sym14020182] [Citation(s) in RCA: 16] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
Boron neutron capture therapy (BNCT) is a binary type of radiotherapy for the treatment of cancer. Due to recent developments of neutron accelerators and their installation in some hospitals, BNCT is on the rise worldwide and is expected to have a significant impact on patient treatments. Therefore, there is an increasing need for improved boron delivery agents. Among the many small molecules and delivery systems developed, a significant amount of recent research focused on the synthesis of boron-containing sugar and amino acid derivatives to exploit specific transport proteins, as d-glucose transporter 1 (GLUT1) and large neutral amino acid transporter (LAT1), overexpressed by tumor cells. This review will discuss the last year’s achievements in the synthesis and some biological evaluation of boronated sugars derivatives. The compounds described in this review are intrinsically asymmetric due to the presence of chiral sugar moieties, often joined to boron clusters, which are structural elements with high symmetry.
Collapse
|
5
|
Burdenkova AV, Zhdanov AP, Klyukin IN, Selivanov NA, Bykov AY, Zhizhin KY, Kuznetsov NT. Synthesis of Derivatives of closo-Dodecaborate Anion Based on Amino Acid Esters. RUSS J INORG CHEM+ 2021. [DOI: 10.1134/s0036023621110036] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Abstract
This work proposes a new method for the synthesis of N-borylated amino acids based on nucleophilic substitution reactions in the [B12H11IPh]– anion. Esters of glycine and L-phenylalanine were used as nucleophiles. The structure of the products has been determined by multinuclear NMR spectroscopy, IR spectroscopy, and ESI mass spectrometry.
Collapse
|
6
|
Matović J, Järvinen J, Sokka IK, Imlimthan S, Raitanen JE, Montaser A, Maaheimo H, Huttunen KM, Peräniemi S, Airaksinen AJ, Sarparanta M, Johansson MP, Rautio J, Ekholm FS. Exploring the Biochemical Foundations of a Successful GLUT1-Targeting Strategy to BNCT: Chemical Synthesis and In Vitro Evaluation of the Entire Positional Isomer Library of ortho-Carboranylmethyl-Bearing Glucoconjugates. Mol Pharm 2020; 18:285-304. [PMID: 33390018 DOI: 10.1021/acs.molpharmaceut.0c00917] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
Boron neutron capture therapy (BNCT) is a noninvasive binary therapeutic modality applicable to the treatment of cancers. While BNCT offers a tumor-targeting selectivity that is difficult to match by other means, the last obstacles preventing the full harness of this potential come in the form of the suboptimal boron delivery strategies presently used in the clinics. To address these challenges, we have developed delivery agents that target the glucose transporter GLUT1. Here, we present the chemical synthesis of a number of ortho-carboranylmethyl-substituted glucoconjugates and the biological assessment of all positional isomers. Altogether, the study provides protocols for the synthesis and structural characterization of such glucoconjugates and insights into their essential properties, for example, cytotoxicity, GLUT1-affinity, metabolism, and boron delivery capacity. In addition to solidifying the biochemical foundations of a successful GLUT1-targeting approach to BNCT, we identify the most promising modification sites in d-glucose, which are critical in order to further develop this strategy toward clinical use.
Collapse
Affiliation(s)
- Jelena Matović
- Department of Chemistry, University of Helsinki, P.O. Box 55, FI-00014 Helsinki, Finland
| | - Juulia Järvinen
- School of Pharmacy, University of Eastern Finland, P.O. Box 1627, FI-70211 Kuopio, Finland
| | - Iris K Sokka
- Department of Chemistry, University of Helsinki, P.O. Box 55, FI-00014 Helsinki, Finland
| | - Surachet Imlimthan
- Department of Chemistry, University of Helsinki, P.O. Box 55, FI-00014 Helsinki, Finland
| | - Jan-Erik Raitanen
- Department of Chemistry, University of Helsinki, P.O. Box 55, FI-00014 Helsinki, Finland
| | - Ahmed Montaser
- School of Pharmacy, University of Eastern Finland, P.O. Box 1627, FI-70211 Kuopio, Finland
| | - Hannu Maaheimo
- VTT Technical Research Centre of Finland Ltd., P.O. Box 1000, FI-02044 VTT, Finland
| | - Kristiina M Huttunen
- School of Pharmacy, University of Eastern Finland, P.O. Box 1627, FI-70211 Kuopio, Finland
| | - Sirpa Peräniemi
- School of Pharmacy, University of Eastern Finland, P.O. Box 1627, FI-70211 Kuopio, Finland
| | - Anu J Airaksinen
- Department of Chemistry, University of Helsinki, P.O. Box 55, FI-00014 Helsinki, Finland.,Turku PET Centre, Department of Chemistry, University of Turku, P.O. Box 52, FI-20521 Turku, Finland
| | - Mirkka Sarparanta
- Department of Chemistry, University of Helsinki, P.O. Box 55, FI-00014 Helsinki, Finland
| | - Mikael P Johansson
- Department of Chemistry, University of Helsinki, P.O. Box 55, FI-00014 Helsinki, Finland.,Helsinki Institute of Sustainability Science, HELSUS, FI-00014 Helsinki, Finland.,CSC-IT Center for Science Ltd., P.O. Box 405, FI-02101 Espoo, Finland
| | - Jarkko Rautio
- School of Pharmacy, University of Eastern Finland, P.O. Box 1627, FI-70211 Kuopio, Finland
| | - Filip S Ekholm
- Department of Chemistry, University of Helsinki, P.O. Box 55, FI-00014 Helsinki, Finland
| |
Collapse
|
7
|
Matović J, Järvinen J, Bland HC, Sokka IK, Imlimthan S, Ferrando RM, Huttunen KM, Timonen J, Peräniemi S, Aitio O, Airaksinen AJ, Sarparanta M, Johansson MP, Rautio J, Ekholm FS. Addressing the Biochemical Foundations of a Glucose-Based "Trojan Horse"-Strategy to Boron Neutron Capture Therapy: From Chemical Synthesis to In Vitro Assessment. Mol Pharm 2020; 17:3885-3899. [PMID: 32787269 PMCID: PMC7539299 DOI: 10.1021/acs.molpharmaceut.0c00630] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2020] [Revised: 08/05/2020] [Accepted: 08/11/2020] [Indexed: 12/12/2022]
Abstract
Boron neutron capture therapy (BNCT) for cancer is on the rise worldwide due to recent developments of in-hospital neutron accelerators which are expected to revolutionize patient treatments. There is an urgent need for improved boron delivery agents, and herein we have focused on studying the biochemical foundations upon which a successful GLUT1-targeting strategy to BNCT could be based. By combining synthesis and molecular modeling with affinity and cytotoxicity studies, we unravel the mechanisms behind the considerable potential of appropriately designed glucoconjugates as boron delivery agents for BNCT. In addition to addressing the biochemical premises of the approach in detail, we report on a hit glucoconjugate which displays good cytocompatibility, aqueous solubility, high transporter affinity, and, crucially, an exceptional boron delivery capacity in the in vitro assessment thereby pointing toward the significant potential embedded in this approach.
Collapse
Affiliation(s)
- Jelena Matović
- Department
of Chemistry, University of Helsinki, Finland, P.O. Box 55, FI-00014 Helsinki, Finland
| | - Juulia Järvinen
- School
of Pharmacy, University of Eastern Finland, P.O. Box 1627, FI-70211 Kuopio, Finland
| | - Helena C. Bland
- Department
of Chemistry, University of Helsinki, Finland, P.O. Box 55, FI-00014 Helsinki, Finland
| | - Iris K. Sokka
- Department
of Chemistry, University of Helsinki, Finland, P.O. Box 55, FI-00014 Helsinki, Finland
| | - Surachet Imlimthan
- Department
of Chemistry, University of Helsinki, Finland, P.O. Box 55, FI-00014 Helsinki, Finland
| | - Ruth Mateu Ferrando
- Department
of Chemistry, University of Helsinki, Finland, P.O. Box 55, FI-00014 Helsinki, Finland
| | - Kristiina M. Huttunen
- School
of Pharmacy, University of Eastern Finland, P.O. Box 1627, FI-70211 Kuopio, Finland
| | - Juri Timonen
- School
of Pharmacy, University of Eastern Finland, P.O. Box 1627, FI-70211 Kuopio, Finland
| | - Sirpa Peräniemi
- School
of Pharmacy, University of Eastern Finland, P.O. Box 1627, FI-70211 Kuopio, Finland
| | - Olli Aitio
- Glykos
Finland Ltd., Viikinkaari
6, FI-00790 Helsinki, Finland
| | - Anu J. Airaksinen
- Department
of Chemistry, University of Helsinki, Finland, P.O. Box 55, FI-00014 Helsinki, Finland
- Turku
PET Centre, Department of Chemistry, University
of Turku, P.O. Box 52, FI-20521 Turku, Finland
| | - Mirkka Sarparanta
- Department
of Chemistry, University of Helsinki, Finland, P.O. Box 55, FI-00014 Helsinki, Finland
| | - Mikael P. Johansson
- Department
of Chemistry, University of Helsinki, Finland, P.O. Box 55, FI-00014 Helsinki, Finland
- Helsinki
Institute of Sustainability Science, HELSUS, FI-00014 Helsinki, Finland
| | - Jarkko Rautio
- School
of Pharmacy, University of Eastern Finland, P.O. Box 1627, FI-70211 Kuopio, Finland
| | - Filip S. Ekholm
- Department
of Chemistry, University of Helsinki, Finland, P.O. Box 55, FI-00014 Helsinki, Finland
| |
Collapse
|
8
|
Swain BR, Mahanta CS, Jena BB, Beriha SK, Nayak B, Satapathy R, Dash BP. Preparation of dendritic carboranyl glycoconjugates as potential anticancer therapeutics. RSC Adv 2020; 10:34764-34774. [PMID: 35514375 PMCID: PMC9056817 DOI: 10.1039/d0ra07264h] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2020] [Accepted: 09/10/2020] [Indexed: 01/22/2023] Open
Abstract
A series of carborane-appended glycoconjugates containing three and six glucose and galactose moieties have been synthesized via Cu(i)-catalyzed azide-alkyne [3 + 2] click cycloaddition reaction. The carboranyl glycoconjugates containing three glucose and galactose moieties were found to be partially water soluble whereas increasing the number to six made them completely water soluble. The evaluation of cytotoxicities and IC50 values of newly synthesized carboranyl glycoconjugates was carried out using two cancerous cell lines (MCF-7 breast cancer cells and A431 skin cancer cells) and one normal cell line (HaCaT skin epidermal cell line). All carboranyl glycoconjugates showed higher cytotoxicities towards cancerous cell lines than the normal cell line. Carboranyl glycoconjugates containing three glucose and galactose moieties (compounds 15 and 17) were found to be more cytotoxic than the glycoconjugates containing six glucose and galactose moieties (compounds 19 and 21). Moreover, administration of 100 μM concentrations of compounds 15 and 17 inhibited up to 83% of MCF-7 breast cancer cells and up to 79% A431 skin cancer cells. However, administration of similar concentrations of carboranyl glycoconjugates could inhibit only up to 35-45% of HaCaT normal epidermal cells. Thus, due to the higher cytotoxicities of dendritic carboranyl glycoconjugates towards cancer cells over healthy cells, they could potentially be useful for bimodal treatment of cancer such as chemotherapy agents and boron neutron capture therapy (BNCT) agents as well.
Collapse
Affiliation(s)
- Biswa Ranjan Swain
- Department of Chemistry, Ravenshaw University Cuttack Odisha 753 003 India
- Department of Chemistry, Siksha 'O' Anusandhan (Deemed to be University) Bhubaneswar Odisha 751030 India
| | | | | | - Swaraj Kumar Beriha
- Department of Chemistry, Siksha 'O' Anusandhan (Deemed to be University) Bhubaneswar Odisha 751030 India
| | - Bismita Nayak
- Department of Life Science, National Institute of Technology Rourkela Odisha 769 008 India
| | | | - Barada P Dash
- Department of Chemistry, Siksha 'O' Anusandhan (Deemed to be University) Bhubaneswar Odisha 751030 India
| |
Collapse
|
9
|
Tsurubuchi T, Shirakawa M, Kurosawa W, Matsumoto K, Ubagai R, Umishio H, Suga Y, Yamazaki J, Arakawa A, Maruyama Y, Seki T, Shibui Y, Yoshida F, Zaboronok A, Suzuki M, Sakurai Y, Tanaka H, Nakai K, Ishikawa E, Matsumura A. Evaluation of a Novel Boron-Containing α-D-Mannopyranoside for BNCT. Cells 2020; 9:E1277. [PMID: 32455737 PMCID: PMC7290312 DOI: 10.3390/cells9051277] [Citation(s) in RCA: 30] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2020] [Revised: 05/18/2020] [Accepted: 05/18/2020] [Indexed: 12/18/2022] Open
Abstract
Boron neutron capture therapy (BNCT) is a unique anticancer technology that has demonstrated its efficacy in numerous phase I/II clinical trials with boronophenylalanine (BPA) and sodium borocaptate (BSH) used as 10B delivery agents. However, continuous drug administration at high concentrations is needed to maintain sufficient 10B concentration within tumors. To address the issue of 10B accumulation and retention in tumor tissue, we developed MMT1242, a novel boron-containing α-d-mannopyranoside. We evaluated the uptake, intracellular distribution, and retention of MMT1242 in cultured cells and analyzed biodistribution, tumor-to-normal tissue ratio and toxicity in vivo. Fluorescence imaging using nitrobenzoxadiazole (NBD)-labeled MMT1242 and inductively coupled mass spectrometry (ICP-MS) were performed. The effectiveness of BNCT using MMT1242 was assessed in animal irradiation studies at the Kyoto University Research Reactor. MMT1242 showed a high uptake and broad intracellular distribution in vitro, longer tumor retention compared to BSH and BPA, and adequate tumor-to-normal tissue accumulation ratio and low toxicity in vivo. A neutron irradiation study with MMT1242 in a subcutaneous murine tumor model revealed a significant tumor inhibiting effect if injected 24 h before irradiation. We therefore report that 10B-MMT1242 is a candidate for further clinical BNCT studies.
Collapse
Affiliation(s)
- Takao Tsurubuchi
- Department of Neurosurgery, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba 305-8575, Japan; (M.S.); (F.Y.); (K.N.); (E.I.); (A.M.)
| | - Makoto Shirakawa
- Department of Neurosurgery, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba 305-8575, Japan; (M.S.); (F.Y.); (K.N.); (E.I.); (A.M.)
- Department of Pharmaceutical Sciences, University of Fukuyama, 1 Sanzo, Gakuen-cho, Fukuyama 729-0292, Japan
| | - Wataru Kurosawa
- Institute for Innovation, Ajinomoto Co., Inc., 1-1 Suzukichō, Kawasaki-ku, Kawasaki 210-8681, Japan; (W.K.); (K.M.); (R.U.); (H.U.); (Y.S.); (J.Y.); (A.A.); (Y.M.); (T.S.); (Y.S.)
| | - Kayo Matsumoto
- Institute for Innovation, Ajinomoto Co., Inc., 1-1 Suzukichō, Kawasaki-ku, Kawasaki 210-8681, Japan; (W.K.); (K.M.); (R.U.); (H.U.); (Y.S.); (J.Y.); (A.A.); (Y.M.); (T.S.); (Y.S.)
| | - Risa Ubagai
- Institute for Innovation, Ajinomoto Co., Inc., 1-1 Suzukichō, Kawasaki-ku, Kawasaki 210-8681, Japan; (W.K.); (K.M.); (R.U.); (H.U.); (Y.S.); (J.Y.); (A.A.); (Y.M.); (T.S.); (Y.S.)
| | - Hiroshi Umishio
- Institute for Innovation, Ajinomoto Co., Inc., 1-1 Suzukichō, Kawasaki-ku, Kawasaki 210-8681, Japan; (W.K.); (K.M.); (R.U.); (H.U.); (Y.S.); (J.Y.); (A.A.); (Y.M.); (T.S.); (Y.S.)
| | - Yasuyo Suga
- Institute for Innovation, Ajinomoto Co., Inc., 1-1 Suzukichō, Kawasaki-ku, Kawasaki 210-8681, Japan; (W.K.); (K.M.); (R.U.); (H.U.); (Y.S.); (J.Y.); (A.A.); (Y.M.); (T.S.); (Y.S.)
| | - Junko Yamazaki
- Institute for Innovation, Ajinomoto Co., Inc., 1-1 Suzukichō, Kawasaki-ku, Kawasaki 210-8681, Japan; (W.K.); (K.M.); (R.U.); (H.U.); (Y.S.); (J.Y.); (A.A.); (Y.M.); (T.S.); (Y.S.)
| | - Akihiro Arakawa
- Institute for Innovation, Ajinomoto Co., Inc., 1-1 Suzukichō, Kawasaki-ku, Kawasaki 210-8681, Japan; (W.K.); (K.M.); (R.U.); (H.U.); (Y.S.); (J.Y.); (A.A.); (Y.M.); (T.S.); (Y.S.)
| | - Yutaka Maruyama
- Institute for Innovation, Ajinomoto Co., Inc., 1-1 Suzukichō, Kawasaki-ku, Kawasaki 210-8681, Japan; (W.K.); (K.M.); (R.U.); (H.U.); (Y.S.); (J.Y.); (A.A.); (Y.M.); (T.S.); (Y.S.)
| | - Takuya Seki
- Institute for Innovation, Ajinomoto Co., Inc., 1-1 Suzukichō, Kawasaki-ku, Kawasaki 210-8681, Japan; (W.K.); (K.M.); (R.U.); (H.U.); (Y.S.); (J.Y.); (A.A.); (Y.M.); (T.S.); (Y.S.)
| | - Yusuke Shibui
- Institute for Innovation, Ajinomoto Co., Inc., 1-1 Suzukichō, Kawasaki-ku, Kawasaki 210-8681, Japan; (W.K.); (K.M.); (R.U.); (H.U.); (Y.S.); (J.Y.); (A.A.); (Y.M.); (T.S.); (Y.S.)
| | - Fumiyo Yoshida
- Department of Neurosurgery, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba 305-8575, Japan; (M.S.); (F.Y.); (K.N.); (E.I.); (A.M.)
| | - Alexander Zaboronok
- Department of Neurosurgery, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba 305-8575, Japan; (M.S.); (F.Y.); (K.N.); (E.I.); (A.M.)
| | - Minoru Suzuki
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2 Asashiro-Nishi, Kumatori-cho, Sennan-gun, Osaka 590-0494, Japan; (M.S.); (Y.S.); (H.T.)
| | - Yoshinori Sakurai
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2 Asashiro-Nishi, Kumatori-cho, Sennan-gun, Osaka 590-0494, Japan; (M.S.); (Y.S.); (H.T.)
| | - Hiroki Tanaka
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2 Asashiro-Nishi, Kumatori-cho, Sennan-gun, Osaka 590-0494, Japan; (M.S.); (Y.S.); (H.T.)
| | - Kei Nakai
- Department of Neurosurgery, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba 305-8575, Japan; (M.S.); (F.Y.); (K.N.); (E.I.); (A.M.)
- Department of Radiation Oncology, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba 305-8575, Japan
| | - Eiichi Ishikawa
- Department of Neurosurgery, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba 305-8575, Japan; (M.S.); (F.Y.); (K.N.); (E.I.); (A.M.)
| | - Akira Matsumura
- Department of Neurosurgery, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba 305-8575, Japan; (M.S.); (F.Y.); (K.N.); (E.I.); (A.M.)
| |
Collapse
|
10
|
Hoppenz P, Els-Heindl S, Kellert M, Kuhnert R, Saretz S, Lerchen HG, Köbberling J, Riedl B, Hey-Hawkins E, Beck-Sickinger AG. A Selective Carborane-Functionalized Gastrin-Releasing Peptide Receptor Agonist as Boron Delivery Agent for Boron Neutron Capture Therapy. J Org Chem 2019; 85:1446-1457. [PMID: 31813224 DOI: 10.1021/acs.joc.9b02406] [Citation(s) in RCA: 21] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
Boron neutron capture therapy (BNCT) allows the selective elimination of malignant tumor cells without affecting healthy tissue. Although this binary radiotherapy approach has been known for decades, BNCT failed to reach the daily clinics to date. One of the reasons is the lack of selective boron delivery agents. Using boron loaded peptide conjugates, which address G protein-coupled receptors overexpressed on tumor cells allow the intracellular accumulation of boron. The gastrin-releasing peptide receptor (GRPR) is a well-known target in cancer diagnosis and can potentially be used for BNCT. Here, we present the successful introduction of multiple bis-deoxygalactosyl-carborane building blocks to the GRPR-selective ligand [d-Phe6, β-Ala11, Ala13, Nle14]Bn(6-14) (sBB2L) generating peptide conjugates with up to 80 boron atoms per molecule. Receptor activation was retained, metabolic stability was increased, and uptake into PC3 cells was proven without showing any intrinsic cytotoxicity. Furthermore, undesired uptake into liver cells was suppressed by using l-deoxygalactosyl modified carborane building blocks. Due to its high boron loading and excellent GRPR selectivity, this conjugate can be considered as a promising boron delivery agent for BNCT.
Collapse
Affiliation(s)
- Paul Hoppenz
- Institute of Biochemistry, Faculty of Life Sciences , Leipzig University , Brüderstrasse 34 , 04103 Leipzig , Germany
| | - Sylvia Els-Heindl
- Institute of Biochemistry, Faculty of Life Sciences , Leipzig University , Brüderstrasse 34 , 04103 Leipzig , Germany
| | - Martin Kellert
- Institute of Inorganic Chemistry , Leipzig University , Johannisallee 29 , 04103 Leipzig , Germany
| | - Robert Kuhnert
- Institute of Inorganic Chemistry , Leipzig University , Johannisallee 29 , 04103 Leipzig , Germany
| | - Stefan Saretz
- Institute of Inorganic Chemistry , Leipzig University , Johannisallee 29 , 04103 Leipzig , Germany
| | | | | | - Bernd Riedl
- Bayer AG , Aprather Weg 18A , Wuppertal , Germany
| | - Evamarie Hey-Hawkins
- Institute of Inorganic Chemistry , Leipzig University , Johannisallee 29 , 04103 Leipzig , Germany
| | - Annette G Beck-Sickinger
- Institute of Biochemistry, Faculty of Life Sciences , Leipzig University , Brüderstrasse 34 , 04103 Leipzig , Germany
| |
Collapse
|
11
|
Zhdanov AP, Voinova VV, Klyukin IN, Kubasov AS, Zhizhin KY, Kuznetsov NT. New Synthesis Method of N-Monosubstituted Ammonium-closo-Decaborates. J CLUST SCI 2019. [DOI: 10.1007/s10876-019-01628-2] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
12
|
Jin GF, Ban HS, Nakamura H, Lee JD. o-Carboranylalkoxy-1,3,5-Triazine Derivatives: Synthesis, Characterization, X-ray Structural Studies, and Biological Activity. Molecules 2018; 23:molecules23092194. [PMID: 30200261 PMCID: PMC6225125 DOI: 10.3390/molecules23092194] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2018] [Revised: 08/23/2018] [Accepted: 08/29/2018] [Indexed: 11/16/2022] Open
Abstract
Morpholine- and bis(2-methoxyethyl)amine-substituted 1,3,5-triazine derivatives containing an alkoxy-o-carborane in the 6-position of the triazine ring were successfully synthesized. The molecular structures of the methoxy- and ethoxy-o-carboranyl-1,3,5-triazines were established by X-ray crystallography. In vitro studies showed that the methylene bridged morpholine- and bis(2-methoxyethyl)amine-substituted o-carboranyl-1,3,5-triazines accumulated to high levels in B16 melanoma cells and exhibited higher cytotoxicity than p-boronophenylalanine.
Collapse
Affiliation(s)
- Guo Fan Jin
- School of Pharmacy, Jiangsu University, Zhenjiang 212013, Jiangsu, China.
| | - Hyun Seung Ban
- Metabolic Regulation Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon 34141, Korea.
| | - Hiroyuki Nakamura
- Laboratory for Chemistry and Life Science, Institute of Innovative Research, Tokyo Institute of Technology, 4259 Nagatsuta-cho, Midori-ku, Yokohama 226-8503, Japan.
| | - Jong-Dae Lee
- Department of Chemistry, College of Natural Sciences, Chosun University, 309 Pilmundaero, Dong-gu, Gwangju 61452, Korea.
| |
Collapse
|
13
|
Calabrese G, Daou A, Barbu E, Tsibouklis J. Towards carborane-functionalised structures for the treatment of brain cancer. Drug Discov Today 2017; 23:63-75. [PMID: 28886331 DOI: 10.1016/j.drudis.2017.08.009] [Citation(s) in RCA: 58] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2017] [Revised: 07/03/2017] [Accepted: 08/29/2017] [Indexed: 11/26/2022]
Abstract
Boron neutron capture therapy (BNCT) is a promising targeted chemoradiotherapeutic technique for the management of invasive brain tumors, such as glioblastoma multiforme (GBM). A prerequisite for effective BNCT is the selective targeting of tumour cells with 10B-rich therapeutic moieties. To this end, polyhedral boranes, especially carboranes, have received considerable attention because they combine a high boron content with relative low toxicity and metabolic inertness. Here, we review progress in the molecular design of recently investigated carborane derivatives in light of the widely accepted performance requirements for effective BNCT.
Collapse
Affiliation(s)
- Gianpiero Calabrese
- School of Life Science, Pharmacy and Chemistry, Kingston University London, Penrhyn Road, Kingston-upon-Thames, KT1 2EE, UK.
| | - Anis Daou
- School of Life Science, Pharmacy and Chemistry, Kingston University London, Penrhyn Road, Kingston-upon-Thames, KT1 2EE, UK
| | - Eugen Barbu
- School of Pharmacy and Biomedical Sciences, University of Portsmouth, Portsmouth, PO1 2DT, UK
| | - John Tsibouklis
- School of Pharmacy and Biomedical Sciences, University of Portsmouth, Portsmouth, PO1 2DT, UK
| |
Collapse
|
14
|
Kawasaki R, Sasaki Y, Akiyoshi K. Self-assembled Nanogels of Carborane-bearing Polysaccharides for Boron Neutron Capture Therapy. CHEM LETT 2017. [DOI: 10.1246/cl.161137] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- Riku Kawasaki
- Department of Polymer Chemistry, Graduate School of Engineering, Kyoto University, Katsura, Nishikyo-ku, Kyoto 615-8510
- Japan Science and Technology Agency (JST), The Exploratory Research for Advanced Technology (ERATO), Bio-nanotransporter Project, Katsura, Nishikyo-ku, Kyoto 615-8510
| | - Yoshihiro Sasaki
- Department of Polymer Chemistry, Graduate School of Engineering, Kyoto University, Katsura, Nishikyo-ku, Kyoto 615-8510
| | - Kazunari Akiyoshi
- Department of Polymer Chemistry, Graduate School of Engineering, Kyoto University, Katsura, Nishikyo-ku, Kyoto 615-8510
- Japan Science and Technology Agency (JST), The Exploratory Research for Advanced Technology (ERATO), Bio-nanotransporter Project, Katsura, Nishikyo-ku, Kyoto 615-8510
| |
Collapse
|
15
|
Axtell JC, Kirlikovali KO, Jung D, Dziedzic RM, Rheingold AL, Spokoyny AM. Metal-Free Peralkylation of the closo-Hexaborate Anion. Organometallics 2017. [DOI: 10.1021/acs.organomet.7b00078] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Jonathan C. Axtell
- Department
of Chemistry and Biochemistry, University of California, Los Angeles, 609 Charles E. Young Drive East, Los Angeles, California 90095, United States
| | - Kent O. Kirlikovali
- Department
of Chemistry and Biochemistry, University of California, Los Angeles, 609 Charles E. Young Drive East, Los Angeles, California 90095, United States
| | - Dahee Jung
- Department
of Chemistry and Biochemistry, University of California, Los Angeles, 609 Charles E. Young Drive East, Los Angeles, California 90095, United States
| | - Rafal M. Dziedzic
- Department
of Chemistry and Biochemistry, University of California, Los Angeles, 609 Charles E. Young Drive East, Los Angeles, California 90095, United States
| | - Arnold L. Rheingold
- Department
of Chemistry and Biochemistry, University of California, San Diego, 9500 Gilman Drive, La Jolla, California 92093, United States
| | - Alexander M. Spokoyny
- Department
of Chemistry and Biochemistry, University of California, Los Angeles, 609 Charles E. Young Drive East, Los Angeles, California 90095, United States
- California
NanoSystems Institute, University of California, Los Angeles, California 90025, United States
| |
Collapse
|
16
|
Zhdanov A, Klyukin I, Bykov A, Grigoriev M, Zhizhin K, Kuznetsov N. Nucleophilic addition of alcohols to anionic [2-B10H9NCR]− (R = Et, t-Bu): An approach to producing new borylated imidates. Polyhedron 2017. [DOI: 10.1016/j.poly.2016.11.035] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
17
|
Ay AN, Akar H, Zaulet A, Viňas C, Teixidor F, Zumreoglu-Karan B. Carborane-layered double hydroxide nanohybrids for potential targeted- and magnetically targeted-BNCT applications. Dalton Trans 2017; 46:3303-3310. [DOI: 10.1039/c7dt00100b] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Carborane-intercalated layered double hydroxide nanohybrids (CB-LDH) and a magnesium ferrite (MF) supported-CB-LDH core–shell nanocomposite (CB-LDH@MF) are reported.
Collapse
Affiliation(s)
- Ahmet Nedim Ay
- Department of Chemistry
- Hacettepe University
- 06800 Ankara
- Turkey
| | - Hande Akar
- Department of Chemistry
- Hacettepe University
- 06800 Ankara
- Turkey
| | - Adnana Zaulet
- Institut de Ciència de MaterialsdeBarcelona(ICMAB-CSIC)
- 08193 Bellaterra
- Spain
| | - Clara Viňas
- Institut de Ciència de MaterialsdeBarcelona(ICMAB-CSIC)
- 08193 Bellaterra
- Spain
| | - Francesc Teixidor
- Institut de Ciència de MaterialsdeBarcelona(ICMAB-CSIC)
- 08193 Bellaterra
- Spain
| | | |
Collapse
|